CTOs on the Move

Vera Whole Health

www.verawholehealth.com

 
Vera Whole Health is a market-leading healthcare service that delivers comprehensive, intelligent primary care to employees via employer-funded worksite clinics.   At the core of our philosophy is the belief that behavior change is the only sustainable way to help people live healthier. And we’ve found through experience and research that a person’s peer group is the primary motivator to that behavior change. That is why Vera Whole Health, in addition to offering primary care and health coaching to individuals, invests time and resources into helping companies change their health culture.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Vera Whole Health raised $24M on 04/06/2017
Vera Whole Health raised $10M on 04/10/2020

Similar Companies

ALOOKS SALON

ALOOKS SALON is a Pinole, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Laureate Pharma

Laureate Pharma L.P. is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Capital Royalty L.P.

Capital Royalty L.P. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

A2 Biotherapeutics

A2 is dedicated to pushing the boundaries of science to transform medicine and turn the tide on cancer. We are focused on the next frontier in cell therapy: solid tumors.

Angion

Angion Biomedica Corp. is a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion`s lead product candidate, ANG-3777, is a small molecule designed to mimic the biological activity of hepatocyte growth factor (HGF) to activate the HGF/c-Met pathway, which has a central role in tissue repair and organ recovery. Enrollment is ongoing in a placebo-controlled Phase 3 registration trial examining the efficacy of ANG-3777 in reducing the severity of transplant-associated acute kidney injury, also known as delayed graft function, in patients at risk for kidney dysfunction. ANG-3777 is also in a Phase 2 clinical trial for the treatment of acute kidney injury associated with cardiac surgery involving cardiopulmonary bypass. Angion is also developing ANG-3070, an orally-bioavailable small molecule, as a potential treatment for a variety of chronic fibrotic diseases sharing similar underlying disease-driving pathways identified and targeted using a precision-medicine approach.